Alumis, Inc.
https://www.alumis.co/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alumis, Inc.
Finance Watch: Mega-Rounds Around The World As VCs Spread The Wealth
Private Company Edition: After US-based Alumis and Sionna raised $259m and $182m, respectively, in series C rounds, Tubulis in Munich, Germany brought in €128m ($138.8m) in series B2 cash, while Rakuten – with offices in the US, Europe and Asia – closed a $119m series E round.
Alumis Looks To Stand Out From The TYK2 Crowd With Psoriasis Data
The privately held company announced data at AAD showing high PASI 75 rates in both a randomized Phase II trial and an open-label extension study.
Foresite Sees Plenty Of Investor Interest In Biopharma As It Raises $173m Fund
With its new fund for companies emerging from Foresite Labs, Foresite Capital has raised more than $1bn in new venture capital during the past year to back life science and health care innovation.
Finance Watch: Mega-Rounds Add Up To Another Record Year For Biopharma VC Funding
Private Company Edition: NVCA and Pitchbook data show pharma and biotech companies raised $37.8bn in venture capital in 2021, up 41% from the record $26.8bn total in 2020. Recent mega-rounds include $190m for Maze and $200m for Alumis, and Sound Bioventures raised a €110m fund.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Esker Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice